MedicineChemistry

M. A. Bashir, Chang-Sheng Shao, Mohnad Abdalla, Xin Yu, M. R. Fetisoa, Qing Huang

2026.2.24PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

DOI: 10.1002/prot.70126

tlooto Summary

Findings indicate that GAA directly interacts with MCT1 and MCT4, and uncovers a biphasic binding pattern associated with MCT4, suggesting a biphasic binding behavior.

Abstract

In recent years, the search for novel anticancer agents has increasingly focused on monocarboxylate transporters (MCTs) because of their involvement in tumor metabolism. Ganoderic acid A (GAA), a triterpenoid derived from the medicinal mushroom Ganoderma lucidum, has demonstrated anticancer potential; however, its interaction with MCT isoforms remains insufficiently characterized. In this study, we examined the interaction between GAA and MCT1 and MCT4 using complementary computational and experimental approaches. Full-length structures of MCT1 and MCT4 were predicted using AlphaFold2 and validated with the SAVES server. Molecular docking and molecular dynamics simulations using the known dual inhibitor syrosingopine as a reference indicated that GAA can associate with both MCT1 and MCT4. Cellular thermal shift assay (CETSA) and isothermal dose-response fingerprinting (ITDRF) showed that GAA thermally destabilized both MCT1 and MCT4, supporting a direct protein-compound interaction. Notably, ITDRF analysis revealed enhanced stability of a higher-molecular-weight MCT4, suggesting a biphasic binding behavior. Together, these findings indicate that GAA directly interacts with MCT1 and MCT4, and uncovers a biphasic binding pattern associated with MCT4.

Citation format

BASHIR, M. A., et al. In silico and in vitro analysis of ganoderic acid a binding to human monocarboxylate transporters 1 and 4. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2026, 94(8): 1442–1457.